CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Series G preferred stock	Series H preferred stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated other comprehensive Income (Loss)	Total
Balance - beginning of period at Mar. 02, 2013	$ 1	$ 182,097	$ 904,268	$ 4,280,831	$ (7,765,262)	$ (61,369)	$ (2,459,434)
BALANCE (in shares) at Mar. 02, 2013		1,821	904,268
Increase (Decrease) in Stockholders' Deficit
Net income					249,414		249,414
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $1,681 and $6,042 tax benefit at February 27, 2016 and February 28, 2015 respectively						24,035	24,035
Comprehensive income							273,449
Exchange of restricted shares for taxes			$ (1,341)	(2,452)			(3,793)
Exchange of restricted shares for taxes (in shares)			(1,341)
Issuance of restricted stock			$ 2,743	(2,743)
Issuance of restricted stock (in shares)			2,743
Cancellation of restricted stock			$ (1,212)	1,212
Cancellation of restricted stock (in shares)			(1,212)
Amortization of restricted stock balance				6,146			6,146
Stock-based compensation expense				10,048			10,048
Tax benefit from exercise of stock options and restricted stock vesting				26,665			26,665
Stock options exercised			$ 26,873	6,344			33,217
Stock options exercised (in shares)			26,873
Dividends on preferred stock		$ 8,318		(8,318)
Dividends on preferred stock (in shares)		83
Conversion of convertible debt instruments	$ (1)	$ (190,415)	$ 40,000	150,416
Conversion of convertible debt instruments (in shares)		(1,904)	40,000
Balance - end of period at Mar. 01, 2014			$ 971,331	4,468,149	(7,515,848)	(37,334)	(2,113,702)
BALANCE (in shares) at Mar. 01, 2014			971,331
Increase (Decrease) in Stockholders' Deficit
Net income					2,109,173		2,109,173
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $1,681 and $6,042 tax benefit at February 27, 2016 and February 28, 2015 respectively						(8,516)	(8,516)
Comprehensive income							2,100,657
Exchange of restricted shares for taxes			$ (2,115)	(13,063)			(15,178)
Exchange of restricted shares for taxes (in shares)			(2,115)
Issuance of restricted stock			$ 3,303	(3,303)
Issuance of restricted stock (in shares)			3,303
Cancellation of restricted stock			$ (454)	454
Cancellation of restricted stock (in shares)			(454)
Amortization of restricted stock balance				12,441			12,441
Stock-based compensation expense				10,949			10,949
Tax benefit from exercise of stock options and restricted stock vesting				37,772			37,772
Stock options exercised			$ 16,485	7,612			24,097
Stock options exercised (in shares)			16,485
Conversion of convertible debt instruments			$ 8	12			20
Conversion of convertible debt instruments (in shares)			8
Balance - end of period at Feb. 28, 2015			$ 988,558	4,521,023	(5,406,675)	(45,850)	57,056
BALANCE (in shares) at Feb. 28, 2015			988,558
Increase (Decrease) in Stockholders' Deficit
Net income					165,465		165,465
Other comprehensive income (loss):
Changes in Defined Benefit Plans, net of $1,681 and $6,042 tax benefit at February 27, 2016 and February 28, 2015 respectively						(1,931)	(1,931)
Comprehensive income							163,534
Exchange of restricted shares for taxes			$ (2,045)	(15,461)			(17,506)
Exchange of restricted shares for taxes (in shares)			(2,045)
Issuance of restricted stock			$ 2,751	(2,751)
Issuance of restricted stock (in shares)			2,751
Cancellation of restricted stock			$ (420)	420
Cancellation of restricted stock (in shares)			(420)
Amortization of restricted stock balance				28,342			28,342
Stock-based compensation expense				11,164			11,164
Tax benefit from exercise of stock options and restricted stock vesting				22,466			22,466
Stock options exercised			$ 6,394	4,982			11,376
Stock options exercised (in shares)			6,394
Conversion of convertible debt instruments			$ 24,762	39,327			64,089
Conversion of convertible debt instruments (in shares)			24,762
Shares issued for EnvisionRx acquisition			$ 27,754	213,153			240,907
Shares issued for EnvisionRx acquisition (in shares)			27,754
Balance - end of period at Feb. 27, 2016			$ 1,047,754	$ 4,822,665	$ (5,241,210)	$ (47,781)	$ 581,428
BALANCE (in shares) at Feb. 27, 2016			1,047,754